Impact of Mexico on the Pharmaceutical Industry – Thematic Research

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The Mexico pharmaceutical market was valued at $21.48 billion in 2020. Mexico has a large and rising middle-class population, a favorable environment for private sector investment, a rise in demand for healthcare services, and relatively high drug prices. The growth of the Mexican pharmaceutical market can be attributed to the large and growing middle-class population, the favorable environment for private sector investment, a rise in demand for healthcare services and pharmaceutical products, and increased quality certifications.

Low-cost manufacturing of pharmaceuticals is attracting increasing foreign investment to Mexico. Many US manufacturing companies aiming to reduce dependence on China perceive nearshoring to Mexico or Canada as even more advantageous than reshoring to the US. Since 2020, COVID-19-related supply chain disruptions have caused many US companies to take steps to bring some of their manufacturing closer to home.

Mexico pharmaceutical market overview

Mexico pharmaceutical market overview

For more insights on this report, download a free report sample

What are the key market trends and drivers in the Mexico pharma industry?

The Mexico pharma industry grew significantly with the repeal of the “derecho de planta” law in 2010, part of the country’s economic liberalization under the conservative PAN party, which required all companies selling pharmaceuticals in Mexico to have a manufacturing facility in the country. Although the rising number of middle-class people in Mexico will fuel growing domestic pharma production, there will be limits to the fast pharma growth. Mexico is also heavily dependent on US markets, as the US is one of its best-trading partners.

There has been a trend toward outsourcing specialist operations and care to cut costs and enhance healthcare results. For example, in Mexico, most dialysis treatments are supplied by private corporations that are under contract with governmental healthcare institutions. Additionally, an increase in collaborations with US healthcare providers was observed to provide cardiac care, cancer treatment, and other specialist care in Mexican institutions or for patients to fly to the US.  As a result, hospitals may save money on plants and equipment, materials, medications, and tools, while still having access to some of the most cutting-edge specialty surgical treatments.

What are the key deal types in the Mexico pharmaceutical market?

The key deal types in the Mexico pharmaceutical market are strategic alliances, mergers & acquisitions, contract service agreements, and capital raisings. The most common deal type was strategic alliances, followed by mergers and acquisitions (M&A). This is in line with general deal-making trends in pharma, where there tend to be more partnerships and funding than M&As.

Mexico pharmaceutical market, by deal types

Mexico pharmaceutical market, by deal types

For more deal type insights, download a free report sample

Which are the key companies in the Mexico pharma market?

Some of the key companies in the Mexico pharma market are F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., Boehringer Ingelheim International GmbH, Genomma Lab Internacional SAB de CV, Teva Pharmaceutical Industries Ltd, Laboratorios Serral SA de CV (a subsidiary of Endo International Plc), and Laboratorios Silanes SA de CV.

Market Report Scope

Market size (Year – 2020)

$21.48 billion
Key deal types Strategic Alliances, Mergers & Acquisitions, Contract Service Agreement, and Capital Raisings
Key pharma companies Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., Boehringer Ingelheim International GmbH, Genomma Lab Internacional SAB de CV, Teva Pharmaceutical Industries Ltd, Laboratorios Serral SA de CV (a subsidiary of Endo International Plc), and Laboratorios Silanes SA de CV.


  • This report provides an assessment of the major industry, regulatory, macroeconomic, and technology trends shaping the Mexico pharma industry.
  • It provides a detailed analysis of deals, clinical trials, marketed and pipeline products, and contract manufacturing.
  • It also provides an overview of key regulatory and market access information, market drivers and barriers, and key players in the Mexican pharma sector.

Reasons to Buy

  • See what trends are shaping the Mexican pharma market and driving innovation, including key government policies and strategic initiatives.
  • Get an analysis of Mexico’s strong manufacturing and outsourcing sector, including plans to further strengthen these capabilities.

Table of Contents

1.1. Preface

1.1.1. Table of Contents

1.1.2. Abbreviations

1.1.3. Related Reports

1.2. Executive Summary

1.2.1. Key Findings

1.3. Introduction

1.3.1. Mexico’s Pharma Market: Growing Capabilities but Poor Infrastructure

1.3.2. Key Influencer Twitter Chat Related to Mexico

1.4. Trends

1.4.1. Industry Trends – Large Pharma Companies Are Investing in Mexico

1.4.2. Industry Trends – Mexican Government Commitment to Healthcare Market Growth

1.4.3. Industry Trends – Increasing Manufacturing Potential in Mexico

1.4.4. Industry Trends – The Mexico Pharma Market is Dominated by Generics

1.4.5. Industry Trends – Low Levels of R&D Innovation

1.4.6. Industry Trends – Increasing Investment in Healthtech

1.4.7. Industry Trends – CNS and Infectious Disease Lead the Pharma Market

1.4.8. Industry Trends – Mexico has a Growing Medical Tourism Industry

1.4.9. Regulatory Trends – Regulatory Trends in Mexico

1.4.10. Regulatory Trends – Corruption and Infrastructure Barriers Limit Public Trust

1.5. Value Chain

1.6. Market Analysis

1.6.1. Mexico’s Pharma Market Will See Moderate Growth to 2025

1.6.2. Strategic Alliances Are the Leading Deal Type in Mexico

1.6.3. Licensing Agreements Lead Strategic Alliance Activity in Mexico

1.6.4. Examples of Licensing Agreements in Mexico 2018–2022YTD

1.6.5. Asset Transactions Lead With Majority of M&A Deals in Mexico

1.6.6. Minimal Capital Raising and CSA Activity in Mexico

1.6.7. Examples of Recent Health Technology Deals in Mexico

1.7. Clinical Trials

1.7.1. The Number of Clinical Trials in Mexico

1.7.2. The Majority of Trials in Mexico Are Mid/Late Phase

1.7.3. Infectious Disease Indications Dominate Clinical Trials in Mexico

1.7.4. Major Sponsors of Clinical Trials in Mexico

1.7.5. Top 10 Clinical Trials Sites in Mexico by Historical Volume

1.7.6. Top 10 Clinical Trial Investigators in Mexico by Historical Volume

1.7.7. Top 10 Trials in Mexico by Completed Enrollment Since 2019

1.8. Marketed Products

1.8.1. US Is the Largest Importer of Pharmaceuticals from Mexico

1.8.2. Generics Have the Largest Share of Marketed Drugs in Mexico

1.8.3. Majority of Marketed Drugs in Mexico Target CNS Disorders

1.8.4. Leading Drug Manufacturers in Mexico

1.8.5. The Majority of Marketed Biologics in Mexico Target Infectious Disease

1.8.6. Examples of Mexico-Approved Biologics (Innovator, Vaccines, etc.)

1.8.7. Currently Approved COVID-19 Vaccines in Mexico

1.8.8. Mexico in Top 10 Countries of COVID-19 Vaccinations Administered

1.9. Pipeline Products

1.9.1. Majority of Pipeline Drugs Are in Phase III and Most Are Innovator Biologics

1.9.2. Laboratorios Silanes Leads in Pipeline Products in Mexico

1.9.3. Infectious Disease Leads Pipeline Drug Development in Mexico

1.9.4. Most Innovator Biologics Are in the Infectious Disease Space

1.9.5. Pipeline COVID-19 Vaccines and Treatments in Mexico

1.9.6. Examples of Pipeline COVID-19 Vaccines and Other Treatments in Mexico

1.10. Contract Manufacturing in India

1.10.1. Contract Manufacturing Companies and Facilities in Mexico

1.10.2. CDMO Facilities Distribution in Mexico

1.11. Regulatory and Market Access

1.11.1. Overview of Healthcare System in Mexico

1.11.2. Organization of Healthcare System in Mexico

1.11.3. Drug Approval Process in Mexico

1.11.4. Regulation of Drugs in Mexico – Generics

1.11.5. Regulation of Drugs in Mexico – Biologics and Biosimilars

1.11.6. Market Access for Drugs in Mexico – Drug Pricing

1.11.7. Market Access for Drugs in Mexico – Reimbursement

1.11.8. Market Access for Drugs in Mexico – Regulatory Landscape

1.12. Market Drivers and Barriers

1.12.1. Market Drivers in Mexico

1.12.2. Market Barriers in Mexico

1.13. Companies

1.13.1. Roche

1.13.2. Sanofi

1.13.3. Pfizer

1.13.4. Boehringer Ingelheim

1.13.5. Genomma Lab

1.13.6. Teva

1.13.7. Laboratorios Serral SA de CV

1.13.8. Laboratorios Silanes SA de CV

1.14. Appendix

1.14.1. Bibliography

1.14.2. Key Themes Impacting the Pharmaceutical Industry

1.14.3. Our Thematic Research Methodology

1.14.4. About the Authors

1.14.5. Contact Us

1.14.6. Disclaimer

Frequently asked questions

Impact of Mexico on the Pharmaceutical Industry – Thematic Research thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Impact of Mexico on the Pharmaceutical Industry – Thematic Research was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Heart Failure Epidemiology Analysis and Forecast to 2032
$3,995 | September 2023
Genomics in pharma: genetic engineered T-cells
$250 | September 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Impact of Mexico on the Pharmaceutical Industry – Thematic Research in real time.

  • Access a live Impact of Mexico on the Pharmaceutical Industry – Thematic Research dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.